Why is Cohance Lifesciences Ltd falling/rising?

Recent Price Movements and Market Performance

The stock hit a new 52-week low of ₹369.5 during intraday trading on 27-Jan, marking a significant milestone in its ongoing decline. Over the past week, Cohance Lifesciences has underperformed the benchmark Sensex by a wide margin, with a weekly loss of 6.19% compared to the Sensex’s modest 0.39% decline. This underperformance extends over longer periods as well, with the stock falling 30.25% in the last month and 29.05% year-to-date, while the Sensex has declined by only 3.74% and 3.95% respectively during these intervals.

More strikingly, the stock has delivered a negative return of 61.68% over the past year, in stark contrast to the Sensex’s gain of 8.61%. Even over three and five years, Cohance Lifesciences has lagged the broader market, posting losses of 23.68% and 20.06% respectively, while the Sensex has surged by 37.97% and 72.66% over the same periods.

Technical Indicators and Investor Sentiment

Technical analysis reveals that the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum. The weighted average price indicates that a greater volume of shares has been traded near the day’s low, suggesting selling pressure dominates. Additionally, investor participation appears to be waning, with delivery volumes on 23 Jan falling by 23.28% compared to the five-day average, indicating reduced conviction among buyers.

Liquidity remains adequate for moderate trade sizes, but the persistent decline and subdued volumes highlight a cautious market stance towards the stock.

Fundamental Challenges Weighing on the Stock

Despite a commendable management efficiency reflected in a high return on equity (ROE) of 21.07% and a low debt-to-equity ratio averaging zero, the company’s financial performance has raised concerns. Operating profit growth has been modest at an annual rate of 4.15% over the past five years, indicating limited expansion in core profitability.

More troubling are the recent negative results reported in September 2025. Operating cash flow for the year stood at a low ₹301.03 crores, while profit before tax excluding other income for the latest quarter fell sharply by 42.4% to ₹68.17 crores compared to the previous four-quarter average. Net profit after tax for the last six months also declined by 39.7%, amounting to ₹128.95 crores. These figures point to weakening operational efficiency and profitability pressures.

Valuation metrics further complicate the outlook. The stock trades at a price-to-book value of 3.8, which is considered expensive relative to its ROE of 9.1 in the recent period. Although the valuation aligns with historical averages among peers, the disconnect between price and earnings growth raises questions about sustainability.

Adding to investor apprehension is the fact that 100% of promoter shares are pledged. In volatile or falling markets, such high promoter pledge levels often exert additional downward pressure on share prices, as any margin calls or forced selling can exacerbate declines.

Long-Term Underperformance and Sector Comparison

Cohance Lifesciences has consistently underperformed not only the Sensex but also the broader BSE500 index over multiple time horizons, including the last three years, one year, and three months. This persistent lag highlights structural challenges within the company’s growth trajectory and market positioning.

While the pharmaceutical and biotechnology sector has seen pockets of strength, Cohance’s recent underperformance relative to its sector peers and the broader market underscores the need for investors to carefully assess the risk-reward profile of the stock.

Conclusion: Why the Stock is Falling

The decline in Cohance Lifesciences Ltd’s share price on 27-Jan and over recent periods is primarily attributable to disappointing financial results, including sharply reduced profits and operating cash flows, coupled with a lacklustre long-term growth record. The stock’s technical weakness, evidenced by trading below all major moving averages and falling investor participation, further compounds the negative sentiment.

Moreover, the full pledge of promoter shares introduces an additional risk factor that tends to amplify price declines in bearish market conditions. Despite strong management efficiency and a clean balance sheet, these positives have not been sufficient to offset concerns about profitability and valuation.

Investors should weigh these factors carefully, especially given the stock’s sustained underperformance relative to benchmarks and sector peers. The current market environment suggests continued caution towards Cohance Lifesciences until clearer signs of operational turnaround and earnings recovery emerge.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →